We are live on ! Find out more
AVLSA

Atlas Venture Life Science Advisors Portfolio holdings

AUM $790M
1-Year Est. Return 223.66%
This Fund
S&P 500
This Quarter Est. Return
-38.9%
1 Year Est. Return
+223.66%
3 Year Est. Return
+485.32%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$522M
AUM Growth
-$298M
Cap. Flow
+$65.7M
Cap. Flow %
12.59%
Top 10 Hldgs %
98.65%
Holding
14
New
1
Increased
1
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
SION
Sionna Therapeutics
SION
+$60.4M
2
DYN icon
Dyne Therapeutics
DYN
+$15.9M

Top Sells

Rank Stock Value
1
IRON icon
Disc Medicine
IRON
+$6.95M
2
TECX
Tectonic Therapeutic
TECX
+$3.62M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KYMR icon
1
Kymera Therapeutics
KYMR
$8.25B
$134M 25.69%
4,896,462
– –
IRON icon
2
Disc Medicine
IRON
$2.93B
$118M 22.69%
2,384,456
-125,000
-5% -$6.95M
DYN icon
3
Dyne Therapeutics
DYN
$4.71B
$95.5M 18.3%
9,130,465
+1,111,111
+14% +$15.9M
DAWN
4
DELISTED
Day One Biopharmaceuticals
DAWN
$51M 9.77%
6,430,257
– –
SION
5
Sionna Therapeutics
SION
$2.22B
$38.6M 7.41%
+3,694,020
New +$60.4M
THRD
6
DELISTED
Third Harmonic Bio
THRD
$36.1M 6.92%
10,402,286
– –
KRRO icon
7
Korro Bio
KRRO
$155M
$19.8M 3.79%
1,137,149
– –
VIGL
8
DELISTED
Vigil Neuroscience
VIGL
$10.4M 1.99%
5,836,874
– –
IMA
9
ImageneBio Inc
IMA
$64.2M
$6.42M 1.23%
418,182
– –
JBIO
10
Jade Biosciences
JBIO
$1.17B
$4.52M 0.87%
51,407
– –
QTTB icon
11
Q32 Bio
QTTB
$450M
$3.45M 0.66%
2,092,106
– –
GBIO
12
DELISTED
Generation Bio
GBIO
$3.35M 0.64%
827,948
– –
SPRO icon
13
Spero Therapeutics
SPRO
$66.6M
$220K 0.04%
305,255
– –
TECX
14
Tectonic Therapeutic
TECX
$527M
– –
-78,447
Closed -$3.62M

Similar funds

AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
AT
Avenir Tech Hong Kong $790M AUM 17.91% 1-Year Est. Return
MTWSIF
Mivtachim The Workers Social Insurance Fund Tel Aviv, Israel $789M AUM 73.25% 1-Year Est. Return
VH
V3 Holding Rye, New York $789M AUM 459.57% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
AI
Aperture Investors New York $791M AUM 54.66% 1-Year Est. Return
VCM
Vision Capital Management Portland, Oregon $792M AUM 18.17% 1-Year Est. Return
SWIG
Strategic Wealth Investment Group Louisville, Kentucky $788M AUM 14.6% 1-Year Est. Return

Atlas Venture Life Science Advisors's Q1 2025 Portfolio in Review

As of Q1 2025, Atlas Venture Life Science Advisors held 14 positions worth $522M, down 36% from $820M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Atlas Venture Life Science Advisors deployed $65.7M of net new capital in Q1 2025, opening 1 new position and adding to 1 existing holding. Its largest new stake was Sionna Therapeutics: 3,694,020 shares worth $38.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Disc Medicine, an estimated $6.95M trimmed.

  • Atlas Venture Life Science Advisors's largest Q1 2025 buy was Sionna Therapeutics: 3,694,020 shares worth $38.6M.
  • Atlas Venture Life Science Advisors added most to Dyne Therapeutics in Q1 2025, an estimated $15.9M increase.
  • Atlas Venture Life Science Advisors's biggest Q1 2025 reduction was Disc Medicine, cutting an estimated $6.95M.
  • Atlas Venture Life Science Advisors fully exited Tectonic Therapeutic in Q1 2025, selling an estimated $3.62M.
  • Atlas Venture Life Science Advisors's ten largest holdings make up 99% of its $522M portfolio in Q1 2025.
  • Atlas Venture Life Science Advisors opened 1 new position and closed 1 in Q1 2025.
  • Atlas Venture Life Science Advisors's portfolio value fell 36% quarter-over-quarter to $522M.

Based on Atlas Venture Life Science Advisors's 13F filing for Q1 2025, filed 14 May 2025.